Table 2.
Characteristics of the included studies.
| Author year (ref.) | Country | Number (sex) | Age | Type of disease | Duration of treatment | Control (number at entry) | Treatment group (number at entry) | Time of measures | Type of study |
|---|---|---|---|---|---|---|---|---|---|
| Abbase et al. 201724 | Iraq | 40 (M/F) | 42.62 ± 13.84 | Peptic ulcer disease | 14 days | Standard triple therapy (N = 19) | Curcumin (1500 mg/day) + standard triple therapy (N = 21) | Baseline and after 6 weeks | RCT |
| Alizadeh et al. 201725 | Iran | 60 (M) | 30.27 ± 3.99 | Infertile oligoasthenospermia | 10 weeks | Placebo (n = 30) | Curcumin nanomicelle 80 mg/day (n = 30) | Baseline and end of study | RCT |
| DiSilvestro et al. 201226 | USA | 38 (M/F) | 47.5 ± 10.5 | Healthy | 4 weeks | Placebo (n = 19) | Curcuma Longa root powder 400 mg/day (n = 19) | Before and after treatment | RCT |
| Hejazi et al. 201627 | Iran | 40 (M) | 70.71 ± 8.20 | Prostate cancer treated with radiotherapy | 3 months | Placebo (n = 23) | Curcuminoids 3 g/day (n = 22) | Baseline and after 3 months | RCT |
| Jimenez- Osorio et al. 201628 | Mexico | 101 (M/F) | 40.55 ± 3.05 | Non-diabetic or diabetic proteinuric chronic kidney disease | 8 weeks | Placebo groups: | Turmeric (320 mg curcumin /day: | Before and after treatment | RCT |
| Non-diabetic proteinuric CKD (n = 26) | Non-diabetic proteinuric CKD (n = 24) | ||||||||
| 55.6 ± 1.55 | Diabetic proteinuric CKD (n = 23) | Diabetic proteinuric CKD (n = 28) | |||||||
| Judaki et al. 201718 | Iran | 100 (M/F) | 54.15 ± 16.09 | Chronic gastritis | 4 weeks | Standard triple therapy (N = 50) | Standard triple therapy +Turmeric tablet (700 mg three times/day) (N = 50) | Before and after treatment | RCT |
| Nasseri et al. 201729 | Iran | 68 (M/F) | 26.79 ± 6.57 | P-Thalassemia | 12 weeks | Placebo (n = 34) | Curcumin 1000 mg/day (n = 34) | Baseline and after 12 weeks | RCT |
| Pakfetrat et al. 201519 | Iran | 50 (M) | 53.6 ± 14.7 | Hemodialysis | 8 weeks | Placebo (n = 25) | Turmeric 1500 mg/day (n = 25) | Before and after treatment | RCT |
| patients | |||||||||
| Panahi et al. 201230 | Iran | 96 (M) | 47.9 ± 9.6 | Veterans of the Iraq-Iran war with chronic pruritus | 4 weeks | Placebo (n = 50) | Curcuminoids 1 g/day (n = 46) + 5 mg bioperine | Before and after treatment | RCT |
| Panahi et al. 2014 a31 | Iran | 89 (M) | 50.97 ± 7.27 | Sulfur mustard Iraq-Iran war chronic pulmonary complications | 4 weeks | placebo (n = 44) | Curcuminoids 1500 mg/day + piperine 15 mg/day (n = 45) | Before and after treatment | RCT |
| Panahi et al. 2014 b32 | Iran | 80 (M/F) | 58.95 ± 15.31 | Solid cancer | 8 weeks | Placebo (n = 40) | Curcuminoids 900 mg/day (n = 40) | Before and after treatment | RCT |
| Panahi et al. 2015 a33 | Iran | 117 (M/F) | 44.13 ± 9.18 | Metabolic syndrome | 8 weeks | Placebo (n = 58) | Curcuminoids 1 g/day + 10 mg piperine (n = 59) | Before and after treatment | RCT |
| Panahi et al. 2015 b34 | Iran | 40 (M/F) | 57.44 ± 8.91 | Knee Osteoarthritis | 6 weeks | Placebo (n= 21) | Curcuminoid 1500 mg/day + 15 mg piperine (n= 19) | Before and after treatment | RCT |
| Panahi et al. 201620 | Iran | 118 (M/F) | 42 ± 7.5 | Type 2 diabetes | 8 weeks | Placebo | Curcuminoids 1000 mg/day + piperine 10 mg | Before and after treatment | RCT |
| Roohi et al. 201735 | Iran | 22 (M) | 24.85 ± 2.2 | Active healthy males | 1 week | Placebo (n = 11) | Curcuminoids 90 mg (n = 11) | Before and after treatment | RCT |
| Srivastava et al. 201636 | India | 160 (M/F) | 50.25 ± 8.35 | Osteoarthritis of knee | 4 months | Placebo (n = 82) | Curcuma longa extract 1000 mg/day (n = 78) | At day 0, 60, and 120 | RCT |
| Sudheeran et al. 201621 | India | 60 (M/F) | 33 ± 7 | Occupational stress- related anxiety and fatigue | 30 days | Placebo (n = 20) | Formulated curcuminoids 1000 mg/day (n = 20) | Before and after treatment | RCT |
| Standard curcuminoids (782 mg curcumin) (n = 20) |
Male (M); female (F); randomized controlled trial (RCT); Age was expressed as mean ± SD or range.